Publications by authors named "Brandon Elpers"
Article Synopsis
- The study aimed to explore the use of antifibrotic therapies in patients with idiopathic pulmonary fibrosis (IPF), focusing on treatment prevalence, patient characteristics, discontinuation rates, and healthcare resource utilization (HCRU) and costs involved.
- It utilized data from two U.S. claims databases, the Clinformatics Data Mart and the Veterans Health Administration, analyzing information on patients diagnosed with IPF between 2013 and 2019.
- Findings revealed that the prevalence of antifibrotic treatment was relatively low (9.2% in Clinformatics and 29.1% in VHA), with high discontinuation rates (47% and 66%, respectively), while treated patients had more healthcare visits and incurred higher
Article Synopsis
- Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are severe lung diseases that require new treatments, prompting a study on the oral drug admilparant (BMS-986278).
- A phase 2, randomized, double-blind trial was conducted with 278 IPF patients and 125 PPF patients, who received either 30mg or 60mg of admilparant or a placebo twice daily for 26 weeks, all while allowing background treatments.
- Results showed that the 60mg dose of admilparant significantly slowed the decline in lung function compared to placebo for both IPF and PPF, with a favorable safety profile, supporting further research in phase 3
Introduction: Idiopathic pulmonary fibrosis (IPF) and non-IPF, progressive fibrotic interstitial lung diseases (PF-ILD), are associated with a progressive loss of lung function and a poor prognosis. Treatment with antifibrotic agents can slow, but not halt, disease progression, and treatment discontinuation because of adverse events is common. Fibrotic diseases such as these can be mediated by lysophosphatidic acid (LPA), which signals via six LPA receptors (LPA).
View Article and Find Full Text PDF